Literature DB >> 30129194

Modeling the dynamics of hepatitis B infection, immunity, and drug therapy.

Stanca M Ciupe1.   

Abstract

Hepatitis B virus infection is the cause of liver diseases such as cirrhosis and liver cancer. Understanding the host-virus mechanisms that mediate virus pathogenesis can help design better preventive measures for disease control. Mathematical models have been used alongside experimental data to provide insight into the role of immune responses during the acute and chronic hepatitis B infections as well as virus dynamics following administration of combined drug therapy. In this paper, we review several modeling studies on virus-host interactions during acute infection, the virus-host characteristics responsible for transition to chronic disease, and the efficacy and optimal control measures of drug therapy. We conclude by presenting our opinion on the future directions of the field.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990HBVzzm321990; HBeAg; drug therapy; mathematical modeling; optimal control

Mesh:

Year:  2018        PMID: 30129194     DOI: 10.1111/imr.12686

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

1.  Model Averaging in Viral Dynamic Models.

Authors:  Antonio Gonçalves; France Mentré; Annabelle Lemenuel-Diot; Jérémie Guedj
Journal:  AAPS J       Date:  2020-02-13       Impact factor: 4.009

2.  Validated Models of Immune Response to Virus Infection.

Authors:  Amber M Smith
Journal:  Curr Opin Syst Biol       Date:  2018-10-31

3.  Introduction to modeling viral infections and immunity.

Authors:  Alan S Perelson; Ruy M Ribeiro
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

4.  Machine learning for mathematical models of HCV kinetics during antiviral therapy.

Authors:  Alexander Churkin; Stephanie Kriss; Asher Uziel; Ashish Goyal; Rami Zakh; Scott J Cotler; Ohad Etzion; Amir Shlomai; Horacio G Rotstein; Harel Dahari; Danny Barash
Journal:  Math Biosci       Date:  2021-12-06       Impact factor: 2.144

Review 5.  Leveraging Computational Modeling to Understand Infectious Diseases.

Authors:  Adrianne L Jenner; Rosemary A Aogo; Courtney L Davis; Amber M Smith; Morgan Craig
Journal:  Curr Pathobiol Rep       Date:  2020-09-24

6.  A correlation analysis of the serum hepcidin concentrations and viral loads in HCV-infected patients.

Authors:  Rongqi Wang; Suxian Zhao; Jinghua Du; Jie Qiao; Wencong Li; Yuemin Nan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

7.  Survivin expression starts before hepatocellular cancer development in the liver of chronic hepatitis B patients: a pilot, cross-sectional study.

Authors:  Muhammet Yener Akpinar; Gulcin Guler Simsek; Evrim Kahramanoglu Aksoy; Ferda Pirincci Sapmaz; Selen Kantarci; Metin Uzman; Yasar Nazligul
Journal:  Prz Gastroenterol       Date:  2019-08-08

8.  Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.

Authors:  Sarah Kadelka; Harel Dahari; Stanca M Ciupe
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

9.  Early events in hepatitis B infection: the role of inoculum dose.

Authors:  Stanca M Ciupe; Naveen K Vaidya; Jonathan E Forde
Journal:  Proc Biol Sci       Date:  2021-02-10       Impact factor: 5.349

10.  Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2.

Authors:  Juliano Ferrari Gianlupi; Tarunendu Mapder; T J Sego; James P Sluka; Sara K Quinney; Morgan Craig; Robert E Stratford; James A Glazier
Journal:  Viruses       Date:  2022-03-14       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.